{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:41:06Z","timestamp":1783579266856,"version":"3.55.0"},"reference-count":39,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>This review explores the use of point-of-care (POC) monitoring of direct oral anticoagulants (DOACs) in patients with non-valvular AF globally and in Malaysia. As patent protection measures for innovative medicines come to an end, and generic alternatives become available, we expect a greater uptake of DOACs than warfarin by patients due to cost advantages. However, the anticoagulation effect of DOACs has been shown to vary from patient to patient and is associated with thrombotic and bleeding risks. Despite the availability of laboratory technology, including at POC, that can monitor the pharmacological effects of DOACs, it has not achieved any substantial traction in clinical use to date. Future efforts should focus on establishing the therapeutic window or \u2018sweet spot\u2019 of DOAC therapy for the POC assays and ensuring adherence before implementation of POC monitoring. This is crucial for the tailoring of anticoagulation therapy, potentially reducing overall healthcare costs and improving patient health outcomes.<\/jats:p>","DOI":"10.15420\/ecr.2024.37","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T10:35:17Z","timestamp":1755167717000},"source":"Crossref","is-referenced-by-count":1,"title":["Systematic Scoping on Point-of-care Monitoring of Direct Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation: Current Status and Future Perspectives in Malaysia"],"prefix":"10.15420","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1426-5117","authenticated-orcid":false,"given":"Shirley Siang Ning","family":"Tan","sequence":"first","affiliation":[{"name":"Clinical Research Centre, Sarawak General Hospital, Institute for Clinical Research, National Institutes of Health, Ministry of Health,  Kuching, Sarawak, Malaysia; Department of Pharmacy, Sarawak General Hospital, Ministry of Health, Kuching, Sarawak, Malaysia; Faculty of Resource Science and Technology, Universiti Malaysia Sarawak, Samarahan, Sarawak, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6433-4259","authenticated-orcid":false,"given":"Wei Hong","family":"Lai","sequence":"additional","affiliation":[{"name":"Clinical Research Centre, Sarawak General Hospital, Institute for Clinical Research, National Institutes of Health, Ministry of Health,  Kuching, Sarawak, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0233-5165","authenticated-orcid":false,"given":"Lee Len","family":"Tiong","sequence":"additional","affiliation":[{"name":"Clinical Research Centre, Sarawak General Hospital, Institute for Clinical Research, National Institutes of Health, Ministry of Health,  Kuching, Sarawak, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3510-1181","authenticated-orcid":false,"given":"Lawrence","family":"Anchah","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak, Samarahan, Sarawak, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8652-8495","authenticated-orcid":false,"given":"Edmund Ui Hang","family":"Sim","sequence":"additional","affiliation":[{"name":"Faculty of Resource Science and Technology, Universiti Malaysia Sarawak, Samarahan, Sarawak, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6675-1312","authenticated-orcid":false,"given":"Alan Yean Yip","family":"Fong","sequence":"additional","affiliation":[{"name":"Clinical Research Centre, Sarawak General Hospital, Institute for Clinical Research, National Institutes of Health, Ministry of Health,  Kuching, Sarawak, Malaysia; Department of Cardiology, Sarawak Heart Centre, Ministry of Health, Samarahan, Sarawak, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"ref0","unstructured":"European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369\u2013429. https:\/\/doi.org\/10.1093\/eurheartj\/ehq278; PMID:\u00a020802247."},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Lim CW, Kasim S, Ismail JR, et al. Prevalence of atrial fibrillation in the Malaysian communities. Heart Asia 2016;8:62\u20136. https:\/\/doi.org\/10.1136\/heartasia-2016-010775; PMID:\u00a027933105.","DOI":"10.1136\/heartasia-2016-010775"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983\u20138. https:\/\/doi.org\/10.1161\/01.str.22.8.983; PMID:\u00a01866765.","DOI":"10.1161\/01.str.22.8.983"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Stroke prevention in atrial fibrillation study. Final results. Circulation 1991;84:527\u201339. https:\/\/doi.org\/10.1161\/01.cir.84.2.527; PMID:\u00a01860198.","DOI":"10.1161\/01.cir.84.2.527"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Schwarb H, Tsakiris DA. New direct oral anticoagulants (DOAC) and their use today. Dent J (Basel) 2016;4:5. https:\/\/doi.org\/10.3390\/dj4010005; PMID:\u00a029563447.","DOI":"10.3390\/dj4010005"},{"key":"ref5","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561; PMID:\u00a019717844."},{"key":"ref6","unstructured":"Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1107039; PMID:\u00a021870978."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638; PMID:\u00a021830957.","DOI":"10.1056\/nejmoa1009638"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Rottenstreich A, Zacks N, Kleinstern G, et al. Direct-acting oral anticoagulant drug level monitoring in clinical patient\u00a0management. J Thromb Thrombolysis 2018;45:543\u20139. https:\/\/doi.org\/10.1007\/s11239-018-1643-0; PMID:\u00a029532414.","DOI":"10.1007\/s11239-018-1643-0"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Chao TF, Chan YH, Tsai PC, et al. Prothrombin time-international normalized ratio predicts the outcome of atrial fibrillation patients taking Rivaroxaban. Biomedicines 2022;10:3210. https:\/\/doi.org\/10.3390\/biomedicines10123210; PMID:\u00a036551966.","DOI":"10.3390\/biomedicines10123210"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"\u0160kor\u0148ov\u00e1 I, Samo\u0161 M, Bolek T, et al. Direct oral anticoagulants plasma levels in patients with atrial fibrillation at the time of bleeding: a pilot prospective study.\u00a0J Cardiovasc Pharmacol 2021;78:e122\u20137. https:\/\/doi.org\/10.1097\/FJC.0000000000001038; PMID:\u00a034173805.","DOI":"10.1097\/FJC.0000000000001038"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Testa S, Tripodi A, Legnani C, et al. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics. Thromb Res 2016;137:178\u201383. https:\/\/doi.org\/10.1016\/j.thromres.2015.12.001; PMID:\u00a026672898.","DOI":"10.1016\/j.thromres.2015.12.001"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Testa S, Legnani C, Antonucci E, et al. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost 2019;17:1064\u201372. https:\/\/doi.org\/10.1111\/jth.14457; PMID:\u00a031013383.","DOI":"10.1111\/jth.14457"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Dimatteo C, D\u2019Andrea G, Vecchione G, et al. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res 2016;144:1\u20135. https:\/\/doi.org\/10.1016\/j.thromres.2016.05.025; PMID:\u00a027261537.","DOI":"10.1016\/j.thromres.2016.05.025"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Testa S, Paoletti O, Legnani C, et al. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost 2018;16:842\u20138. https:\/\/doi.org\/10.1111\/jth.14001; PMID:\u00a029532628.","DOI":"10.1111\/jth.14001"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Woodruff AE, Wovkulich MM, Mogle BT, Hassan AK. Association between prothrombin time and bleeding in hospitalized patients receiving rivaroxaban. Am J Health Syst Pharm 2018;75:1783\u20139. https:\/\/doi.org\/10.2146\/ajhp180031; PMID:\u00a030049684.","DOI":"10.2146\/ajhp180031"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Wada S, Toyoda K, Sato S, et al. Anti-Xa activity and event risk in patients with direct factor Xa inhibitors initiated early after stroke. Circ J 2018;82:2872\u20139. https:\/\/doi.org\/10.1253\/circj.CJ-18-0506; PMID:\u00a030210082.","DOI":"10.1253\/circj.cj-18-0506"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Bernier M, Lancrerot SL, Parassol N, et al. Therapeutic drug monitoring of direct oral anticoagulants may increase their benefit-risk ratio. J Cardiovasc Pharmacol 2020;76:472\u20137. https:\/\/doi.org\/10.1097\/FJC.0000000000000870; PMID:\u00a033030858.","DOI":"10.1097\/FJC.0000000000000870"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Flaker GC, Theriot P, Binder LG, et al. Management of periprocedural anticoagulation: a survey of contemporary practice. J Am Coll Cardiol 2016;68:217\u201326. https:\/\/doi.org\/10.1016\/j.jacc.2016.04.042; PMID:\u00a027386777.","DOI":"10.1016\/j.jacc.2016.04.042"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Patel JP, Byrne RA, Patel RK, Arya R. Progress in the monitoring of direct oral anticoagulant therapy. Br J Haematol 2019;184:912\u201324. https:\/\/doi.org\/10.1111\/bjh.15756; PMID:\u00a030697708.","DOI":"10.1111\/bjh.15756"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Arksey H, O\u2019Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol 2005;8:19\u201332. https:\/\/doi.org\/10.1080\/1364557032000119616.","DOI":"10.1080\/1364557032000119616"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Daudt HM, van Mossel C, Scott SJ. Enhancing the scoping study methodology: a large, inter-professional team\u2019s experience with Arksey and O\u2019Malley\u2019s framework. BMC Med Res Methodol 2013;13:48. https:\/\/doi.org\/10.1186\/1471-2288-13-48; PMID:\u00a023522333.","DOI":"10.1186\/1471-2288-13-48"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Levac D, Colquhoun H, O\u2019Brien KK. Scoping studies: advancing the methodology. Implement Sci 2010;5:69. https:\/\/doi.org\/10.1186\/1748-5908-5-69; PMID:\u00a020854677.","DOI":"10.1186\/1748-5908-5-69"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Sahli SD, Castellucci C, Roche TR, et al. The impact of direct oral anticoagulants on viscoelastic testing: a systematic review. Front Cardiovasc Med 2022;9:991675. https:\/\/doi.org\/10.3389\/fcvm.2022.991675; PMID:\u00a036419490.","DOI":"10.3389\/fcvm.2022.991675"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Lingervelder D, Koffijberg H, Kusters R, IJzerman MJ. Health economic evidence of point-of-care testing: a systematic review. Pharmacoecon Open 2021;5:157\u201373. https:\/\/doi.org\/10.1007\/s41669-020-00248-1; PMID:\u00a033405188.","DOI":"10.1007\/s41669-020-00248-1"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Baglin T, Hillarp A, Tripodi A, et al. Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013;11:756\u201360. https:\/\/doi.org\/10.1111\/jth.12149; PMID:\u00a023347120.","DOI":"10.1111\/jth.12149"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Asmis LM, Alberio L, Angelillo-Scherrer A, et al. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 2012;129:492\u20138. https:\/\/doi.org\/10.1016\/j.thromres.2011.06.031; PMID:\u00a021840043.","DOI":"10.1016\/j.thromres.2011.06.031"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Willekens G, Studt JD, Mendez A, et al. A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation. Br J Haematol 2021;193:1203\u201312. https:\/\/doi.org\/10.1111\/bjh.17470; PMID:\u00a033954979.","DOI":"10.1111\/bjh.17470"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Gosselin RC, Adcock DM, Douxfils J. An update on laboratory assessment for direct oral anticoagulants (DOACs). Int J Lab Hematol 2019;41(Suppl 1):33\u20139. https:\/\/doi.org\/10.1111\/ijlh.12992; PMID:\u00a031069969.","DOI":"10.1111\/ijlh.12992"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc 2020;9:e017559. https:\/\/doi.org\/10.1161\/JAHA.120.017559; PMID:\u00a032538234.","DOI":"10.1161\/JAHA.120.017559"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Harenberg J, Martini A, Du S, et al. Performance characteristics of DOAC dipstick in determining direct oral anticoagulants in urine. Clin Appl Thromb Hemost 2021;27:1076029621993550. https:\/\/doi.org\/10.1177\/1076029621993550; PMID:\u00a033733904.","DOI":"10.1177\/1076029621993550"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Papageorgiou L, Hetjens S, Fareed J, et al. Comparison of the DOAC dipstick test on urine samples with chromogenic substrate methods on plasma samples in outpatients treated with direct oral anticoagulants. Clin Appl Thromb Hemost 2023;29:10760296231179684. https:\/\/doi.org\/10.1177\/10760296231179684; PMID:\u00a037278029.","DOI":"10.1177\/10760296231179684"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Sokol J, Nehaj F, Ivankova J, et al. Impact of dabigatran treatment on rotation thromboelastometry. Clin Appl Thromb Hemost 2021;27:1076029620983902. https:\/\/doi.org\/10.1177\/1076029620983902; PMID:\u00a033523711.","DOI":"10.1177\/1076029620983902"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Sch\u00e4fer ST, Otto AC, Acevedo AC, et al. Point-of-care detection and differentiation of anticoagulant therapy: development of thromboelastometry-guided decision-making support algorithms. Thromb J 2021;19:63. https:\/\/doi.org\/10.1186\/s12959-021-00313-7; PMID:\u00a034493301.","DOI":"10.1186\/s12959-021-00313-7"},{"key":"ref34","unstructured":"Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330\u201393. https:\/\/doi.org\/10.1093\/eurheartj\/ehy136; PMID:\u00a029562325."},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Par\u00e9 G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013;127:1404\u201312. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.001233; PMID:\u00a023467860.","DOI":"10.1161\/circulationaha.112.001233"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Sychev DA, Levanov AN, Shelekhova TV, et al. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. Pharmacogenomics Pers Med 2018;11:127\u201337. https:\/\/doi.org\/10.2147\/PGPM.S169277; PMID:\u00a030100750.","DOI":"10.2147\/PGPM.S169277"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Leong LK, Tan SSN, Tiong LL, et al. Predictors of thromboembolic events in patients prescribed with dabigatran in Malaysia. Int J Cardiol 2023;393:131452. https:\/\/doi.org\/10.1016\/j.ijcard.2023.131452.","DOI":"10.1016\/j.ijcard.2023.131452"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Fong AYY, Tiong LL, Tan SSN, et al. Effect of dabigatran on clotting time in the Clotpro ecarin clotting assay: a prospective, single-arm, open-label study. Clin Appl Thromb Hemost 2020;26:1076029620972473. https:\/\/doi.org\/10.1177\/1076029620972473; PMID:\u00a033284050.","DOI":"10.1177\/1076029620972473"}],"container-title":["European Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2024.37","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T10:35:26Z","timestamp":1755167726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2024.37"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":39,"URL":"https:\/\/doi.org\/10.15420\/ecr.2024.37","relation":{},"ISSN":["1758-3764","1758-3756"],"issn-type":[{"value":"1758-3764","type":"electronic"},{"value":"1758-3756","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"article-number":"e21"}}